EGF+61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma

被引:54
作者
McCarron, SL
Bateman, AC
Theaker, JM
Howell, WM
机构
[1] Southampton Univ Hosp, Histocompatibil & Immunogenet Lab, Southampton SO16 6YD, Hants, England
[2] Univ Southampton, Div Human Genet, Southampton, Hants, England
[3] Southampton Gen Hosp, Dept Cellular Pathol, Southampton SO9 4XY, Hants, England
关键词
EGF+61; single nucleotide polymorphism; malignant melanoma;
D O I
10.1002/ijc.11448
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CMM is the most serious cutaneous malignancy and is increasing in frequency among most Caucasian populations, where the most important risk factor is exposure to UV light. Relatively little is known of the genetic factors that mediate susceptibility to and prognosis in sporadic CMM, although a number of genes have been implicated. A striking association between EGF polymorphism and Breslow thickness of invasive CMM has been reported. We have sought confirmation of this finding in an independent study of 159 patients and 3 10 controls using TaqMan fluorescence-based genotyping for EGF +61. In our study group, there were no significant differences in EGF genotype frequencies between patients and controls nor was EGF genotype associated with tumour growth phase, stage or mitotic count. However, correlation between EGF genotype and Breslow thickness showed a modestly significant increase in frequency of the EGF (G/G) genotype among tumours >3.5 mm thick (30.0% vs. 9.8%, p = 0.03). In summary, in our group, the EGF +61 polymorphism was not a risk factor for CMM susceptibility, but this polymorphism may play a role in disease progression. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:673 / 675
页数:3
相关论文
共 17 条
[1]   Liver metastatic ability of human melanoma cell line is associated with losses of chromosomes 4, 9p21-pter and 10p [J].
Adám, Z ;
Adány, R ;
Ladányi, A ;
Tímár, J ;
Balázs, M .
CLINICAL & EXPERIMENTAL METASTASIS, 2000, 18 (04) :295-302
[2]   HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population [J].
Bateman, AC ;
Turner, SJ ;
Theaker, JM ;
Howell, WM .
TISSUE ANTIGENS, 1998, 52 (01) :67-73
[3]   Incidence of cutaneous melanoma among non-Hispanic Whites, Hispanics, Asians, and Blacks: An analysis of California Cancer Registry data, 1988-93 [J].
Cress, RD ;
Holly, EA .
CANCER CAUSES & CONTROL, 1997, 8 (02) :246-252
[4]   Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma [J].
Howell, WM ;
Bateman, A ;
Turner, SJ ;
Collins, A ;
Theaker, JM .
GENES AND IMMUNITY, 2002, 3 (04) :229-232
[5]   IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma [J].
Howell, WM ;
Turner, SJ ;
Bateman, AC ;
Theaker, JM .
GENES AND IMMUNITY, 2001, 2 (01) :25-31
[6]  
Hutchinson PE, 2000, CLIN CANCER RES, V6, P498
[7]   Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color [J].
Kennedy, C ;
ter Huurne, J ;
Berkhout, M ;
Gruis, N ;
Bastiaens, M ;
Bergman, W ;
Willemze, R ;
Bavinck, JNB .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) :294-300
[8]  
Kumar R, 2001, INT J CANCER, V95, P388, DOI 10.1002/1097-0215(20011120)95:6<388::AID-IJC1069>3.0.CO
[9]  
2-6
[10]   PHENOTYPE OF GLUTATHIONE-S-TRANSFERASE MU (GSTM1) AND SUSCEPTIBILITY TO MALIGNANT-MELANOMA [J].
LAFUENTE, A ;
MOLINA, R ;
PALOU, J ;
CASTEL, T ;
MORAL, A ;
TRIAS, M ;
MASCARO, JM ;
VILALTA, A ;
TRIAS, M ;
PIULACHS, J ;
BALLESTA, A ;
ESTIVILL, X ;
ESTAPE, J .
BRITISH JOURNAL OF CANCER, 1995, 72 (02) :324-326